Download PDF
Int J Angiol 2021; 30(02): 132-138
DOI: 10.1055/s-0040-1720969
Original Article

Curcumin's Effect on Inflammatory Response following Percutaneous Coronary Intervention in Adult Patients with Stable Coronary Heart Disease

Todung Silalahi
1   Division of Cardiovascular, Department of Internal Medicine, Faculty of Medicine Krida Wacana Christian University, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia
,
Idrus Alwi
2   Division Cardiovascular, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia
,
Frans Suyatna
3   Department of Clinical Pharmacology, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia
,
Katarina D. Sartika
1   Division of Cardiovascular, Department of Internal Medicine, Faculty of Medicine Krida Wacana Christian University, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Cardiovascular diseases play major roles in the health problems worldwide especially in Indonesia. Percutaneous coronary intervention (PCI) is a minimally invasive procedure with relatively low complications. However, high inflammatory response post-PCI has showed adverse events even after administration of standard medication. Previous studies showed that curcumin was able to reduce inflammatory response in adult patients with stable coronary heart disease (CHD). This article determines the efficacy of oral administration of curcumin in reducing inflammatory response post-PCI with stable CHD. A double-blind randomized controlled trial on 50 adult patients comparing curcumin and placebo was performed in Cipto Mangunkusumo General Hospital and Jakarta Heart Center within April and June 2015. Either curcumin (45 mg/day) or placebo was given 7 days prior to PCI until 2 days after PCI. Inflammatory markers (high-sensitivity C-reactive protein [hsCRP] and soluble CD40 ligand [sCD40L]) were measured in three phases (7 days prior PCI, 24 hours post-PCI, and 48 hours post-PCI). There were no significant differences in the reduction of hsCRP and sCD40L between curcumin and placebo groups in three phases of measurement. Curcumin significantly reduce the serum hsCRP (p = 0.006) and sCD40L (p = 0.002) 7 days before PCI to 48 hours post-PCI. The decrement of hsCRP (−14.2% vs. –7.4%) and sCD40L (−24.3% vs. –13.2%) from 24 to 48 hours post-PCI was higher in the curcumin group than placebo group. The administration of curcumin 45 mg dose daily for 7 days prior PCI until 48 hours post-PCI is useful in reducing inflammatory response post-PCI with stable CHD.

Keywords

curcumin - inflammatory response - PCI - stable CHD


Publication History

Article published online:
29 January 2021

© 2021. International College of Angiology. This article is published by Thieme.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Estimates GH. Deaths, Disability-Adjusted Life Year (DALYs), Years of Life Lost (YLL) and Years Lost due to Disability (YLD) by Cause, Age and Sex, 2000–2012. Geneva: World Health Organization; 2012
    Google Scholar
  • 2 Ministry of Health Republic of Indonesia. Basic Health Research. Jakarta: 2013. https://www.kemkes.go.id/resources/download/general/Hasil%20Riskesdas%202013.pdf
    Google Scholar
  • 3 Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet 1978; 1 (8058): 263
    CrossrefPubMedGoogle Scholar
  • 4 Means G, End C, Kaul P. Management of percutaneous coronary intervention complications. Curr Treat Options Cardiovasc Med 2017; 19 (04) 25
    CrossrefPubMedGoogle Scholar
  • 5 Kalkman DN, Aquino M, Claessen BE. et al. Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions. Eur Heart J 2018; 39 (46) 4101-4108
    CrossrefPubMedGoogle Scholar
  • 6 Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 1991; 253 (5024): 1129-1132
    CrossrefPubMedGoogle Scholar
  • 7 Holmes Jr DR, Vlietstra RE, Smith HC. et al. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. Am J Cardiol 1984; 53 (12) 77C-81C
    CrossrefPubMedGoogle Scholar
  • 8 Levine GN, Bates ER, Blankenship JC. et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124 (23) e574-e651
    PubMedGoogle Scholar
  • 9 Nobuyoshi M, Kimura T, Nosaka H. et al. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol 1988; 12 (03) 616-623
    CrossrefPubMedGoogle Scholar
  • 10 Serruys PW, Luijten HE, Beatt KJ. et al. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation 1988; 77 (02) 361-371
    CrossrefPubMedGoogle Scholar
  • 11 Kapakos G, Youreva V, Srivastava AK. Cardiovascular protection by curcumin: molecular aspects. Indian J Biochem Biophys 2012; 49 (05) 306-315
    PubMedGoogle Scholar
  • 12 Mirzabeigi P, Mohammadpour AH, Salarifar M, Gholami K, Mojtahedzadeh M, Javadi MR. The effect of curcumin on some of traditional and non-traditional cardiovascular risk factors: a pilot randomized, double-blind, placebo-controlled trial. Iran J Pharm Res 2015; 14 (02) 479-486
    PubMedGoogle Scholar
  • 13 Alwi I. Hubungan faktor metabolik dengan respons infllamasi pada sindrom koroner akut pasien diabetes mellitus tipe 2. Universitas Indonesia; 2006
    Google Scholar
  • 14 Cheng ALHC, Hsu CH, Lin JK. et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001; 21 (4B): 2895-2900
    PubMedGoogle Scholar
  • 15 Lao CD, Ruffin IV MT, Normolle D. et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006; 6: 10
    CrossrefPubMedGoogle Scholar
  • 16 Sharma RA, McLelland HR, Hill KA. et al. Pharmacodynamic and pharmacokinetic study of oral curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001; 7 (07) 1894-1900
    PubMedGoogle Scholar
  • 17 Tsimikas S, Lau HK, Han KR. et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation 2004; 109 (25) 3164-3170
    CrossrefPubMedGoogle Scholar
  • 18 Kim TH, Jiang HH, Youn YS. et al. Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity. Int J Pharm 2011; 403 (1-2): 285-291
    CrossrefPubMedGoogle Scholar
  • 19 Li TT, Xie Y, Guo Y. et al. Effect of probucol on vascular remodeling due to atherosclerosis in rabbits: an intravascular ultrasound study. Chin Med J (Engl) 2011; 124 (12) 1840-1847
    PubMedGoogle Scholar
  • 20 DiSilvestro RA, Joseph E, Zhao S, Bomser J. Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutr J 2012; 11: 79
    CrossrefPubMedGoogle Scholar